BiotechTube
Stilla Technologies

Stilla Technologies

Paris, France· Est.
stillatechnologies.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $54M

Overview

Stilla Technologies, founded in 2016 and based in Paris, is a leader in multiplex digital PCR technology. The company's core innovation is the Nio® platform, which offers 7-color detection, continuous loading, and high sample throughput, addressing key limitations in traditional dPCR and qPCR. Its technology is applied in critical areas such as cancer mutation detection, CRISPR quality control, and viral vector analytics, serving academic, clinical, and biopharmaceutical customers. In 2024, Stilla Technologies was acquired by Bio-Rad Laboratories, significantly enhancing its global commercial reach and resources.

OncologyGenetic DisordersInfectious Diseases

Technology Platform

Nio® digital PCR system featuring 7-color multiplex detection, continuous loading, high-throughput (768 samples/day), and microfluidic ruby chip partitioning for absolute nucleic acid quantification.

Funding History

2
Total raised:$54M
Series B$34M
Series A$20M

Opportunities

The acquisition by Bio-Rad provides massive global commercial distribution, sales support, and R&D funding to accelerate adoption of the 7-color Nio® platform.
Growing demand in liquid biopsy, cell & gene therapy analytics, and infectious disease surveillance creates expansive markets for high-multiplex, quantitative DNA detection.

Risk Factors

Integration into the larger Bio-Rad organization must be managed carefully to preserve innovative agility and customer focus.
The company faces intense competition from other dPCR vendors and alternative technologies like NGS.
Converting customers from established workflows requires demonstrating clear superior value and cost-effectiveness.

Competitive Landscape

Stilla competes in the digital PCR market against established leaders like Bio-Rad's own ddPCR™ systems and Thermo Fisher's QuantStudio Absolute Q dPCR system. Its primary competitive advantage is superior 7-color multiplexing versus the typical 4-6 colors offered by rivals. Other competitors include QIAGEN and niche players, but the Bio-Rad acquisition now positions Stilla's technology as a premium, high-plex offering within a market-leading portfolio.

More companies in Diagnostics & Precision Medicine →More companies in France →